Is Cav1.3 a feasible therapeutic target for a rare neurodevelopmental disorder?

Expert Opin Ther Targets. 2024 Dec 19:1-5. doi: 10.1080/14728222.2024.2442428. Online ahead of print.

Author

Nadine J Ortner¹

Affiliation

¹ Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.

PMID: 39670814
DOI: 10.1080/14728222.2024.2442428

No abstract available

Keywords: CACNA1D; Ca2+ channel blockers; Cav1.3 Ca2+ channels; de novo missense mutations; dihydropyridines; neurodevelopmental disease.

Publication types

Editorial